Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS). At three years, XIENCE V demonstrated a 43 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS
"The SPIRIT III results clearly demonstrate that at three years, patients continue to benefit from having been treated with the XIENCE V stent rather than the TAXUS stent, with fewer repeat cardiac procedures and fewer heart attacks in patients who received XIENCE V," said Dr. Stone, who is also immediate past chairman of the Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III trial.
XIENCE V demonstrated an impressive low rate of very late stent thrombosis (one to three years) with no additional events between two and three years. Per protocol, XIENCE V demonstrated a 0.2 percent** very late stent thrombosis rate compared to 1.0 percent for TAXUS>
Key Results from SPIRIT III
In the 1,002-patient SPIRIT III trial, XIENCE V demonstrated the following key results out to three years:
- A 43 percent reduction in the risk of MACE compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS,>
- A 43 percent reduction in the risk of Target Lesion Failure (TLF) compared to TAXUS (8.3 percent for XIENCE V vs. 14.4 percent for TAXUS,>
- A 30 percent reduction in the risk of Target Vessel Failure (TVF) compared to TAXUS (13.5 percent for XIENCE V vs. 19.2 percent for TAXUS,>
- A 42 percent reduction in the risk of heart attacks (MI) compared to TAXUS (3.7 percent for XIENCE V vs. 6.3 percent for TAXUS,>
- A 39 percent reduction in the risk of ID-TLR compared to TAXUS (5.4 percent for XIENCE V vs. 8.9 percent for TAXUS,>
- Per protocol definition, a 0.2 percent** rate of very late stent thrombosis compared to 1.0 percent for TAXUS>
Consistent Results in SPIRIT III Subgroup Analyses